The effect of the
prostacyclin analog
U-68,215 on gastric function and systemic blood pressure was evaluated in a primate model. Starting 30 min after
histalog (1 mg/kg s.c.), gastric acid secretion and gastric emptying were determined over a 30-min period using a 99mTc-diethylene triamine pentaacetic
acid dilution technique. Each animal then received an intragastric bolus of 0, 25, 50 or 100 micrograms/kg of
U-68,215 and, after a 30-min equilibration period, gastric function was determined for an additional 60 min (
histalog +
U-68,215). Systemic blood pressure and heart rate were measured periodically using a pressure cuff and a Korotkoff microphone.
U-68,215 produced a 94% maximum suppression of
acid output from 60 to 90 min after 100 micrograms/kg
U-68,215. Gastric emptying was significantly inhibited by all doses of
U-68,215, and no
diarrhea was observed in response to any dose of
U-68,215. Systolic blood pressure was significantly inhibited (P less than .05) only after the 100 micrograms/kg, whereas diastolic blood pressure was reduced significantly (P less than .05) by both 50 and 100 micrograms/kg and was positively correlated with
acid secretion (r = .53; P less than .05). These data demonstrate that
U-68,215 produces a significant inhibition of
acid secretion without the stimulatory effect on gastric emptying induced by
PGE analogs. Thus,
prostacyclin analogs may represent an attractive alternative to
PGE analogs in the treatment of
peptic ulcer disease.